BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the
safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease
progressed on or after a first-line antineoplastic treatment. Patients will receive BKM120
orally at a dose of 100 mg/day. Availability of tumor specimen (either archival tissue or a
fixed fresh biopsy) is mandatory for assessment of the PI3K (Phosphatidylinositol 3 Kinase
(PI3K) pathway activation status.